Table 1.

FES expression and clinicopathological features

	Patients N (%)	Immunoreactive score of FES		p value
		Median, IQR	Mean/SD
Age at diagnosis				0.291
Median or less	102 (50.2)	2.5, 1.5–3.0	2.50/1.47
Over median	101 (49.8)	2.5, 1.5–2.5	2.29/1.45
Sex				0.131
Male	166 (81.8)	2.0, 1.5–3.0	2.57/1.61
Female	37 (18.2)	2.0, 1.0–2.5	2.22/1.40
pT stage				0.039*
Ta	68 (33.5)	2.5, 1.0–4.0	2.76/1.74
T1	100 (49.3)	2.0, 1.5–3.0	2.17/1.21
T2	21 (10.3)	2.5, 1.5–3.0	2.41/1.26
T3	14 (6.9)	3.5, 1.0–6.0	3.46/2.48
Muscle invasion				0.109
Absence: Ta + 1	168 (82.8)	2.0, 1.5–3.0	2.44/1.50
Presence: T2 + 3	35 (17.2)	2.5, 1.5–3.0	2.83/1.89
Grade				0.005
Low	102 (50.2)	2.5, 1.5–4.0	2.83/1.67
High	101 (49.8)	1.5, 1.5–2.5	2.18/1.40

Data of immunoreactive score were showed as median, interquartile range (IQR), and mean/SD

*Significant value was detected between pT1 versus pT3 only